Skip to main content
Top
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Research article

Thymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models

Authors: Jing Yuan, Yan Shen, Xia Yang, Ying Xie, Xin Lin, Wen Zeng, Yingting Zhao, Maolu Tian, Yan Zha

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Background

Thymosin β4 (Tβ4) is closely associated with the cytoskeleton, inflammation, wound healing, angiogenesis, apoptosis, and myocardial regeneration, but the effects of Tβ4 treatment on chronic renal tubular interstitial fibrosis (CRTIF) are poorly known. This study aimed to examine the effects of Tβ4 on the renal apoptosis and the expression of transforming growth factor (TGF-β), E-cadherin, and α-smooth muscle actin (α-SMA) in CRTIF rat models.

Methods

Male SD rats were randomized into four groups (sham group, unilateral ureteral obstruction (UUO) group, UUO + low-dose Tβ4 group, and UUO + high-dose Tβ4 group). The pathological changes of kidney tissue and its function were assessed two weeks after UUO. In renal interstitial tissue,TGF-β, E-cadherin and α-SMA expression was detected by western blot. In tubular epithelial cells, E-cadherin and α-SMA expression was detected using Real-time qPCR and western blot. Cell apoptosis of rat renal interstitial tissue and tubular epithelial cells was evaluated by immunofluorescence and western blot.

Results

Two weeks after UUO, no differences in blood urea nitrogen and creatinine were observed between the four groups (P > 0.05). Compared to the UUO group, Tβ4 treatment decreased the 24-h proteinuria (P < 0.001) and reduced the area of pathological change (P < 0.01); this effect was more apparent in the UUO + high-dose Tβ4 group. Compared to the UUO group, a significant decrease in TGF-β and α-SMA protein expression was observed in the high-dose Tβ4 group. The level of E-cadherin protein was lower in the UUO group than the Tβ4 groups, and high-dose Tβ4 treatment further increased E-cadherin expression and improved cell apoptosis in the renal interstitial tissue. Analysis of in vitro tubular epithelial cells showed that α-SMA mRNA and protein expression decreased, while E-cadherin mRNA and protein expression increased by Tβ4 treatment. Similarly, these changes were more significant in the UUO + high-dose Tβ4 group. Tβ4 treatment improved the apoptosis of In vitro tubular epithelial cells compared with pure TGF-β stimulation, and equally, the decrease of apoptosis was more apparent in the TGF-β + high-dose Tβ4 group.

Conclusions

Tβ4 treatment might alleviate the renal fibrosis and apoptosis of tubular epithelial cells through TGF-β pathway inhibition in UUO rats with CRTIF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:4.CrossRef Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:4.CrossRef
2.
go back to reference Zhang L, Wang F, Wang L, Wang W, Liu B, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–22.CrossRefPubMed Zhang L, Wang F, Wang L, Wang W, Liu B, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–22.CrossRefPubMed
3.
go back to reference Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213–7.CrossRefPubMed Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213–7.CrossRefPubMed
4.
go back to reference Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010;6:643–56.CrossRefPubMed Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010;6:643–56.CrossRefPubMed
5.
go back to reference Qiao X, Li RS, Li H, Zhu GZ, Huang XG, Shao S, et al. Intermedin protects against renal ischemia-reperfusion injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2013;304:F112–9.CrossRefPubMed Qiao X, Li RS, Li H, Zhu GZ, Huang XG, Shao S, et al. Intermedin protects against renal ischemia-reperfusion injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2013;304:F112–9.CrossRefPubMed
6.
go back to reference Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol. 2001;159:1465–75.CrossRefPubMedPubMedCentral Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol. 2001;159:1465–75.CrossRefPubMedPubMedCentral
7.
go back to reference Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol. 2011;301:G950–5.CrossRefPubMedPubMedCentral Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol. 2011;301:G950–5.CrossRefPubMedPubMedCentral
8.
go back to reference Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci U S A. 1966;56:1010–7.CrossRefPubMedPubMedCentral Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci U S A. 1966;56:1010–7.CrossRefPubMedPubMedCentral
9.
go back to reference Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–89.CrossRefPubMed Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–89.CrossRefPubMed
10.
go back to reference Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11:421–9.CrossRefPubMed Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11:421–9.CrossRefPubMed
11.
go back to reference Pai M, Spalding D, Xi F, Habib N. Autologous bone marrow stem cells in the treatment of chronic liver disease. Int J Hepatol. 2012;2012:307165.CrossRefPubMed Pai M, Spalding D, Xi F, Habib N. Autologous bone marrow stem cells in the treatment of chronic liver disease. Int J Hepatol. 2012;2012:307165.CrossRefPubMed
12.
go back to reference Liu C, Mei W, Tang J, Yuan Q, Huang L, Lu M, et al. Mefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstruction. PLoS One. 2015;10:e0129283.CrossRefPubMedPubMedCentral Liu C, Mei W, Tang J, Yuan Q, Huang L, Lu M, et al. Mefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstruction. PLoS One. 2015;10:e0129283.CrossRefPubMedPubMedCentral
13.
go back to reference Zuo Y, Chun B, Potthoff SA, Kazi N, Brolin TJ, Orhan D, et al. Thymosin beta4 and its degradation product, ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int. 2013;84:1166–75.CrossRefPubMedPubMedCentral Zuo Y, Chun B, Potthoff SA, Kazi N, Brolin TJ, Orhan D, et al. Thymosin beta4 and its degradation product, ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int. 2013;84:1166–75.CrossRefPubMedPubMedCentral
14.
go back to reference Moriyama T, Kawada N, Ando A, Horio M, Yamauchi A, Na-gata K, et al. Up-regulation of HSP47 in the mouse kidneys with unilateral ureteral obstruction. Kidney Int. 1998;54:110–9.CrossRefPubMed Moriyama T, Kawada N, Ando A, Horio M, Yamauchi A, Na-gata K, et al. Up-regulation of HSP47 in the mouse kidneys with unilateral ureteral obstruction. Kidney Int. 1998;54:110–9.CrossRefPubMed
15.
go back to reference Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93:440–7.CrossRefPubMed Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93:440–7.CrossRefPubMed
16.
go back to reference Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314–22.CrossRefPubMed Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314–22.CrossRefPubMed
17.
go back to reference Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, Ithakissios DS, et al. Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta. 2001;1568:60–6.CrossRefPubMed Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, Ithakissios DS, et al. Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta. 2001;1568:60–6.CrossRefPubMed
18.
go back to reference Kumar S, Gupta S. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS One. 2011;6:e26912.CrossRefPubMedPubMedCentral Kumar S, Gupta S. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS One. 2011;6:e26912.CrossRefPubMedPubMedCentral
19.
go back to reference Ock MS, Cha HJ, Choi YH. Verifiable hypotheses for thymosin beta4-dependent and -independent angiogenic induction of Trichinella spiralis-triggered nurse cell formation. Int J Mol Sci. 2013;14:23492–8.CrossRefPubMedPubMedCentral Ock MS, Cha HJ, Choi YH. Verifiable hypotheses for thymosin beta4-dependent and -independent angiogenic induction of Trichinella spiralis-triggered nurse cell formation. Int J Mol Sci. 2013;14:23492–8.CrossRefPubMedPubMedCentral
20.
go back to reference Xiao Y, Qu C, Ge W, Wang B, Wu J, Xu L, et al. Depletion of thymosin beta4 promotes the proliferation, migration, and activation of human hepatic stellate cells. Cell Physiol Biochem. 2014;34:356–67.CrossRefPubMed Xiao Y, Qu C, Ge W, Wang B, Wu J, Xu L, et al. Depletion of thymosin beta4 promotes the proliferation, migration, and activation of human hepatic stellate cells. Cell Physiol Biochem. 2014;34:356–67.CrossRefPubMed
21.
go back to reference Kim J, Wang S, Hyun J, Choi SS, Cha H, Ock M, et al. Hepatic stellate cells express thymosin Beta 4 in chronically damaged liver. PLoS One. 2015;10:e0122758.CrossRefPubMedPubMedCentral Kim J, Wang S, Hyun J, Choi SS, Cha H, Ock M, et al. Hepatic stellate cells express thymosin Beta 4 in chronically damaged liver. PLoS One. 2015;10:e0122758.CrossRefPubMedPubMedCentral
22.
go back to reference Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011;25:1815–26.CrossRefPubMedPubMedCentral Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011;25:1815–26.CrossRefPubMedPubMedCentral
23.
go back to reference Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12:37–51.CrossRefPubMed Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12:37–51.CrossRefPubMed
24.
go back to reference Gagliardini E, Benigni A. Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther. 2007;7:293–304.CrossRefPubMed Gagliardini E, Benigni A. Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther. 2007;7:293–304.CrossRefPubMed
25.
go back to reference Tunggal JA, Helfrich I, Schmitz A, Schwarz H, Gunzel D, Fromm M, et al. E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. EMBO J. 2005;24:1146–56.CrossRefPubMedPubMedCentral Tunggal JA, Helfrich I, Schmitz A, Schwarz H, Gunzel D, Fromm M, et al. E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. EMBO J. 2005;24:1146–56.CrossRefPubMedPubMedCentral
26.
go back to reference Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21:212–22.CrossRefPubMed Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21:212–22.CrossRefPubMed
Metadata
Title
Thymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models
Authors
Jing Yuan
Yan Shen
Xia Yang
Ying Xie
Xin Lin
Wen Zeng
Yingting Zhao
Maolu Tian
Yan Zha
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0708-1

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue